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PDCD1, an immunoreceptor involved in peripheral tolerance has previously been shown to be genetically associated with
systemic lupus erythematosus (SLE). PDCD1 has two ligands whose genes are located in close proximity on chromosome
9p24. Our attention was drawn to these ligands after finding suggestive linkage to a marker (gata62f03, Z¼ 2.27) located close
to their genes in a genome scan of Icelandic families multiplex for SLE. Here, we analyse Swedish trios (N¼ 149) for 23 single
nucleotide polymorphisms (SNPs) within the genes of the PDCD1 ligands. Initially, indication of association to eight SNPs was
observed, and these SNPs were therefore also analysed in Mexican trios (N¼ 90), as well as independent sets of patients and
controls from Sweden (152 patients, 448 controls) and Argentina (288 patients, 288 controls). We do not find support for
genetic association to SLE. This is the first genetic study of SLE and the PDCD1 ligands and the lack of association in several
cohorts implies that these genes are not major risk factors for SLE.
Genes and Immunity (2007) 8, 69–74. doi:10.1038/sj.gene.6364360; published online 30 November 2006
Keywords: systemic lupus erythematosus; genetic association; linkage disequilibrium; autoimmunity; PD-L1; PD-L2
Introduction
Systemic lupus erythematosus (SLE) is a multifactorial
autoimmune disease characterized by autoantibodies
directed against molecules found in the nucleus, cyto-
plasm and cell surfaces, accompanied by a wide range of
clinical manifestations, including chronic inflammation
of various tissues and organs. The genetic component of
SLE is strong, with a concordance rate estimated to 24–
69% in monozygotic and 2–3% in dizygotic twins1–3 and
an overall increased risk for relatives of SLE patients.4
A regulatory polymorphism in the gene encoding the
immunoreceptor PDCD1 has previously been reported to
be involved in susceptibility for human SLE.5 We
reasoned that genes encoding molecules that interact
with PDCD1 could also be susceptibility factors. In
Icelandic families, suggestive linkage (Z¼ 2.27) was
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reported to marker gata62f03 on chromosome 9p24.6
This region harbours the genes for the two ligands of
PDCD1, PD-L1 (also CD274) and PD-L2 (also CD273),
which rendered them our main candidates for further
analysis.
PD-L1 is constitutively expressed on B, T, myeloid and
dendritic cells and is upregulated upon activation. It is
also expressed in a wide range of non-haematopoietic
tissues including the heart, lung and pancreas. PD-L2 is
induced on macrophages and dendritic cells.7–10 Many
studies have demonstrated that the PDCD1 pathway has
an inhibitory effect on T cells,11–13 whereas others have
indicated a stimulating effect.14–16 PDCD1/ mice have
been shown to develop arthritis and lupus-like glomer-
ulonephritis.17 Furthermore, in murine models of dia-
betes, colitis and multiple sclerosis, in vivo blockade of
PDCD1 and/or one of its ligands has been shown to
either trigger or augment the disease or to have a
therapeutic effect.18–20 Thus, the connection with auto-
immunity and the role of the PDCD1 pathway in
peripheral tolerance has been well established.
PD-L1 and PD-L2 are located together within a
segment of 120 kilobasepairs (kb) on chromosome 9p24.
PD-L1 is 18 kb in size with seven exons, whereas PD-L2
is located 42 kb downstream of PD-L1 and has equally
many exons, but stretches up to 60 kb.
Owing to the role of the ligands of PDCD1 in
autoimmunity and our previous linkage evidence, we
reasoned these genes were interesting candidates for
genetic association with SLE. However, the data from
this study do not support such an association.
Results
In a continued analysis of the Icelandic multicase
families displaying linkage (Z¼ 2.27) to marker ga-
ta62f03, just 267 kb upstream from the location of PD-
L1 and PD-L2, we sequenced promoter regions and all
exons in eight index cases from these families and eight
Icelandic unrelated controls and identified 11 SNPs
within or adjacent to the exons. We investigated the
inheritance pattern of these SNPs, but found no
significant evidence of association. The genetic material
was, however, relatively small and rather suited for
linkage than association studies. We therefore proceeded
with genotyping of a set of trios from another Scandi-
navian population, namely Swedish.
In total, 23 SNPs within the PD-L1 and PD-L2 genes
were selected for analysis (see Materials and methods
section). Eight were found to be associated to SLE in the
Swedish trios (N¼ 149) when analysed by haplotype-
based haplotype relative risk21 (HHRR). The family-
based association test22 (FBAT) did not, however, detect
any association (Table 1).
Table 1 Allele frequencies of SNPs in PD-L1 and PD-L2 for transmitted and non-transmitted alleles using HHRR and for patients and
population controls
SNP Locationa Sequence
feature
Transmitted
(HHRR)
Patients N/total
N of alleles
Non-transmitted
(HHRR)
Controls N/total
N of alleles
P-value
(HHRR)
P-value
(FBAT)
PD-L1
L111 85 Promoter 1 (0.3%) NT 2 (1.9%) NT NS NS
rs10815225 62 Promoter 27 (9.3%) 36/276 (13.0%) 22 (19.8%) 98/979 (9.8%) 0.0037 NS
rs7866740 29 Promoter 21 (7.3%) 17/274 (6.2%) 18 (15.3%) 74/978 (7.6%) 0.0011 NS
rs17742278 5965 Intronic 74 (30.1%) NT 34 (27.6%) NT NS NS
rs1411262 8862 Intronic 77 (30.6%) NT 34 (27.6%) NT NS NS
rs10815226 9148 Intronic 57 (23.0%) NT 25 (22.9%) NT NS NS
rs7041009 12686 Intronic 77 (30.3%) NT 32 (25.8%) NT NS NS
C39 15529 CNS 48 (17.5%) 42/278 (15.1%) 35 (31.8%) 140/845 (16.6%) 0.0020 NS
L1 73 17244 Intronic 18 (6.3%) 16/272 (5.9%) 17 (14.2%) 64/995 (7.0%) 0.0083 NS
rs2297136 17399 30 UTR 157 (55.3%) 135/294 (45.9%) 58 (40.3%) 465/996 (46.7%) 0.0044 NS
rs4143815 17701 30 UTR 74 (27.4%) NT 38 (32.2%) NT NS NS
rs10118693 33683 CNS 70 (29.7%) NT 36 (36.7%) NT NS NS
C57:2 33799 CNS 2 (0.8%) NT 0 (0.0%) NT NS NS
PD-L2
rs16923189 74 50 UTR 62 (26.1%) NT 32 (29.1%) NT NS NS
C91:1 7641 CNS 2 (0.7%) NT 1 (0.9%) NT NS NS
C91:2 7667 CNS 2 (0.7%) NT 0 (0.0%) NT NS NS
rs12001295 7690 CNS 10 (3.4%) 16/285 (5.6%) 12 (10.1%) 50/840 (5.6%) 0.0053 NS
rs7870226 19447 CNS 83 (33.5%) NT 47 (38.2%) NT NS NS
C103:2 19500 CNS 1 (0.4%) NT 0 (0.0%) NT NS NS
C103:3 19512 CNS 4 (1.5%) NT 3 (2.9%) NT NS NS
rs6476989 45002 CNS 1 (0.4%) NT 0 (0.0%) NT NS NS
rs7854413 47138 Exonic 15 (5.1%) 27/294 (9.2%) 12 (10.7%) 94/1016 (9.3%) 0.029 NS
rs7852996 59290 Intronic 10 (3.6%) 23/243 (8.6%) 12 (11.1%) 68/830 (8.2%) 0.0038 NS
Abbreviations: CNS, conserved non-coding sequence; FBAT, family-based association test; HHRR, haplotype-based haplotype relative risk;
SNPs, single nucleotide polymorphisms; NS, non-significant; NT, not tested.
Results of the association analysis using HHRR and FBAT are shown as well as the location of the SNPs. SNPs with rs-numbers can be found
in databases, other names indicate previously unknown SNPs identified by us. Minor allele frequencies are shown.
aBasepairs from transcription start.
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In order to confirm the association or lack of associa-
tion, we analysed the eight SNPs in a set of Mexican trios
(N¼ 90). Neither HHRR nor FBAT tests were able to
confirm the association (Table 2). The same eight SNPs
were also examined in two sets of patients and unrelated
controls from Sweden (152 patients and 448 controls) and
Argentina (288 patients and 288 controls). No association
was seen in either population (Tables 1 and 3), with the
exception of allele T of L1 73, which in Argentina is
found in 2.0% of patients and 4.5% in controls
(P¼ 0.0157). However, for several reasons stated in
Discussion section, we consider this a false–positive
result.
The Swedish and Argentinean populations are not
similar enough for the two cohorts to be analysed as one,
but a meta-analysis is applicable. We analysed all
patients and controls from Sweden and Argentina using
the Mantel–Haenszel method, and found no association.
Haplotype frequencies estimated using PHASE23,24 did
not differ significantly between patients and controls
(data not shown). A comparison of the degree of linkage
disequilibrium (LD) in patients and controls in our
cohorts found no indications of a conserved risk
haplotype in the patients. The only noticeable difference
was found in the Swedish cohort, where the patients
actually appeared to have a slightly lower degree of LD
than both healthy controls and healthy trio parents (data
not shown).
Ten of the SNPs analysed here have now been
included in the HapMap Project25 (http://www.hapmap.
org). In the European HapMap trios, there are three large
blocks of LD in the region of the PDCD1 ligands.
Roughly estimated, the first block corresponds to PD-L1,
the second block to the intergenic region and the first
exon of PD-L2, and the third block comprises the
remaining six exons of PD-L2. The markers analysed in
this study are localized in 50, middle and 30 regions of
both genes, as well as in the intergenic region and all LD
blocks are represented by at least one SNP (Figure 1).
Discussion
We initially found indications of association between SLE
and eight SNPs within PD-L1 and PD-L2 in Swedish trios
analysed by the HHRR test. However, other statistical
methods applied to the same data set failed to confirm
this association.
Table 2 Frequencies of PD-L1 and PD-L2 polymorphisms in
Mexican trios
SNP Transmitted Non-transmitted
N/total N (%) N/total N (%)
rs10815225 20/168 (11.9) 15/118 (12.7)
rs7866740 8/174 (4.6) 6/120 (5.0)
C39 39/174 (22.4) 34/127 (26.8)
L1 73 8/174 (4.6) 6/122 (4.9)
rs2297136 40/166 (24.1) 31/113 (27.4)
rs12001295 9/176 (5.1) 9/126 (7.1)
rs7854413 18/176 (10.2) 13/125 (10.4)
rs7852996 16/174 (9.2) 9/120 (7.5)
Table 3 Frequencies of PD-L1 and PD-L2 polymorphisms in
Argentinean patients and controls
SNP Patients Controls
N/total N (%) N/total N (%)
rs10815225 69/566 (12.2) 81/560 (14.5)
rs7866740 34/568 (6.0) 32/562 (5.7)
C39 139/572 (24.3) 147/544 (27.0)
L1 73 11/560 (2.0) 25/552 (4.5)
rs2297136a 208/552 (37.7) 201/522 (38.5)
rs12001295 45/570 (7.9) 37/540 (6.9)
rs7854413 60/566 (10.6) 64/566 (11.3)
rs7852996 52/570 (9.1) 57/570 (10.0)
Abbreviation: SNP, single nucleotide polymorphisms.
Minor allele frequencies are shown.
aFor rs2297136 the opposite allele is minor compared with Swedish
and Mexican cohorts.
PD-L1 PD-L2
Figure 1 Pattern of LD according to HapMap data (www.hapmap.org). Dark grey indicates strong LD, light grey to white indicates weak or
no LD. Position of SNPs analysed in this study are indicated by arrows.
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The SNPs that were associated in the Swedish trios
were also analysed in Mexican trios, and in two
independent sets of patients and controls from Sweden
and Argentina. No association was seen in these three
cohorts, except the highly questionable protective asso-
ciation of L1 73 in Argentina. For several reasons we
believe this association to be, most likely, false positive.
First, the risk of type I error is greater for a rare allele
than for a common.26 Second, this Argentinean cohort
has shown to be somewhat heterogeneous with about
20% Amerindian admixture,27 which further increases
the risk of false-positive results owing to population
substructure. Third, a large number of markers have now
been analysed in several cohorts, increasing the prob-
ability of spurious association. If corrected for multiple
testing, the association would become nonsignificant.
There are many different statistical methods for
analysing genetic association. Family-based studies have
the advantage of lower sensitivity to bias owing to
population substructure. On the other hand, bias can be
introduced by inclusion of incomplete families or by
reconstruction of parental genotypes from their off-
spring, causing inflated frequencies of rare alleles in
the family-based controls.28–31 Why we observe associa-
tion with the HHRR test and not FBAT, could perhaps be
explained by the incomplete trios included in our
material. FBAT should be less sensitive to this type of
bias, as it is designed to apply to any type of pedigree,
including incomplete trios.22 Comparison of non-trans-
mitted allele frequencies from our HHRR analysis with
frequencies in the healthy controls further supports this
theory: the frequency of rare alleles is often considerably
higher among nontransmitted than among healthy
controls. Estimated haplotype frequencies did not differ
significantly between patients and controls, and the
degree of LD is not higher in patients than controls,
which provides further evidence for lack of association in
the region.
Power estimations using Quanto32–34 (http://hydra.
usc.edu/GxE/) shows that our case-control cohorts from
Sweden and Argentina each have high power to detect
risk alleles with odds ratio (OR) above 1.5 (Table 4). Our
trios have somewhat lower power than the case–control
cohorts, and as many of our trios are incomplete, the
actual power should be even lower. However, this study
comprises several cohorts, which increases the overall
power of the study substantially. We estimate that the
risk of failing to detect true association in all of the
investigated cohorts is low. Data for risk allele frequen-
cies 0.1, 0.2 and 0.3 and ORs 1.5 and 2.0 are shown in
Table 4. Although the SNPs analysed in this study were
selected as possible functional polymorphisms rather
than ‘tag SNPs’ for the total-genetic variation in these
genes, they are spread across both genes and represent
all LD blocks according to the HapMap data. The
existence of association to a polymorphism of strong
effect in the investigated populations does therefore not
appear very likely. Nevertheless, we cannot exclude the
possibility of a risk factor that is not in LD with any of
the markers analysed in this study. It should be noted
that although the cohorts in this study are mainly of
European descent, the Argentinean and Mexican are
admixed with Amerindians, who have not yet been
included in the HapMap project. Consequently, HapMap
LD patterns may not apply as well to these populations.
We also want to clarify that the functional role that the
ligands of PDCD1 may have in human SLE has not been
the subject of this study.
PDCD1 has in many studies been shown to be
associated not only to SLE, but also rheumatoid arthritis,
type I diabetes and multiple sclerosis.5,35–37 It has been
implied that its ligands also are involved in autoimmu-
nity.18–20 The result of this study, however, does not find a
role for genetic variants of the PDCD1 ligands in SLE
susceptibility. To our knowledge, this is the first study of
genetic association between the PDCD1 ligands and an
autoimmune disease. The absence of association in the
cohorts studied here suggests that these genes are not
major risk factors for SLE.
Materials and methods
Subjects
We studied 149 Swedish trios consisting of SLE patients
and unaffected parents, as well as some unaffected
siblings (58 patients in complete trios, 71 with one parent
sample and 20 with only information from siblings). In
total, 98 healthy siblings were included. We also studied
90 Mexican trios (56 patients in complete trios, 16 with
one parent, and 18 patients with only siblings). In total,
27 siblings and five other close relatives are included. In
addition, two cohorts of patient–control material includ-
ing 152 independent patients and 448 controls from
Sweden, and 288 patients and 288 controls from
Argentina were studied. Ten Icelandic multicase families
previously described6 were also examined. All affected
individuals fulfilled four or more of the American college
of rheumatology’s criteria for SLE.38 This study was
approved by local ethics committees in all countries and
all subjects studied have given their informed consent.
Identification/selection of SNPs
Three approaches were used to identify SNPs: first,
sequencing of all exons of PD-L1 and PD-L2 in SLE
Table 4 Power of cohorts to detect risk factor with frequency of 0.1, 0.2 and 0.3 and odds ratio (OR) of 1.5 or 2.0
Cohort Frequency¼ 0.1 Frequency¼ 0.2 Frequency¼ 0.3
OR¼ 1.5 OR¼ 2.0 OR¼ 1.5 OR¼ 2.0 OR¼ 1.5 OR¼ 2.0
Swedish trios (N¼ 149) 43.0% 82.7% 54.3% 91.2% 56.0% 91.2%
Mexican trios (N¼ 90) 30.8% 64.3% 38.9% 75.3% 40.2% 75.4%
Swedish cases (N¼ 301) and controls (N¼ 488) 74.7% 99.3% 85.8% 99.9% 86.3% 99.8%
Argentinean cases (N¼ 288) and controls (N¼ 288) 64.6% 97.2% 76.9% 99.2% 77.6% 99.1%
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patients and healthy controls identified 11 SNPs within
or adjacent to the exons. Second, sequences of potential
regulatory importance were identified by species se-
quence comparison between human and murine PD-L1
and PD-L2, including the 42 kb intergenic region and
20 kb upstream of PD-L1 using Vista.39,40 Thirteen regions
were conserved non-coding sequences (CNS) with a
threshold of 75% identity in at least 100 bp. Within these
13 CNS, we identified 10 SNPs. We also searched the
introns of PD-L1 for clusters of transcription factor
binding sites (TFBS), with a focus on haematopoietic
transcription factors. Five such clusters were located and
sequenced in patients and controls, identifying one SNP.
SNPs listed in databases were analysed for alteration of
TFBS. One SNP was found to disrupt the binding of
RUNX1, which was implicated in the association of SLE
and PDCD1.5 Thus, a total of 23 SNPs were selected for
analysis.
Genotyping
Swedish trios and Icelandic families were genotyped by
sequencing using BigDye Terminator (Applied Bio-
systems, Foster City, CA, USA) for all SNPs except
rs16923189, which was genotyped by restriction frag-
ment length polymorphism (RFLP) using the enzyme
PvuII. Mexican trios as well as Argentinean and Swedish
patients and controls were genotyped by TaqMan SNP
genotyping assays (Applied Biosystems). Genotypes
determined by RFLP or TaqMan SNP genotyping were
verified by sequencing of randomly selected samples.
Rs7852996 was genotyped by sequencing in all materials,
as other methods failed.
Statistical analysis
All SNPs were in Hardy–Weinberg equilibrium in all
investigated populations. Swedish and Mexican trios
were analysed by HHRR included in the Analyze
software21 and by FBAT.22 For the case–control cohorts,
w2 analysis of 2 2 contingency tables was applied.
Haplotypes were estimated using the PHASE v2.1
software.23,24
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